Khan Mohammed A, DeCroos Francis C, Storey Philip P, Shields Jerry A, Garg Sunir J, Shields Carol L
*Retina Service, Wills Eye Hospital, Philadelphia, Pennsylvania; and †Oncology Service, Wills Eye Hospital, Philadelphia, Pennsylvania.
Retina. 2014 Sep;34(9):1750-6. doi: 10.1097/IAE.0000000000000187.
To investigate the efficacy of serial anti-vascular endothelial growth factor injections for choroidal neovascularization associated with choroidal osteoma.
In this retrospective interventional case series, eyes with choroidal osteoma and associated choroidal neovascularization were treated with intravitreal ranibizumab or bevacizumab with or without photodynamic therapy consolidation. Resolution of subretinal fluid on optical coherence tomography and best-corrected visual acuity were assessed.
Eight eyes in eight patients were treated with monthly intravitreal anti-vascular endothelial growth factor injections with or without photodynamic therapy. Resolution of subretinal fluid on optical coherence tomography was achieved in 7 of 8 eyes (87%) with a mean of 12.3 ± 12.6 injections (range, 1-40). Four eyes (50%) experienced at least 1 recurrence of exudation at a mean interval of 10 months (median, 7.5; range, 5-21 months), necessitating further therapy. The mean Snellen visual acuity improvement was 1 ± 4 lines (range, loss 3 to gain 7 lines) at a mean of 32-months follow-up.
Serial anti-vascular endothelial growth factor therapy alone or with photodynamic therapy consolidation for choroidal neovascularization due to choroidal osteoma resulted in anatomical improvement and modest visual gain.
探讨连续抗血管内皮生长因子注射治疗脉络膜骨瘤相关脉络膜新生血管的疗效。
在这个回顾性介入病例系列中，对患有脉络膜骨瘤及相关脉络膜新生血管的眼睛，采用玻璃体内注射雷珠单抗或贝伐单抗治疗，联合或不联合光动力疗法巩固治疗。评估光学相干断层扫描上视网膜下液的消退情况以及最佳矫正视力。
8例患者的8只眼睛接受了每月一次的玻璃体内抗血管内皮生长因子注射，联合或不联合光动力疗法。8只眼中有7只（87%）在光学相干断层扫描上视网膜下液消退，平均注射12.3±12.6次（范围1 - 40次）。4只眼（50%）至少出现1次渗出复发，平均间隔10个月（中位数7.5；范围5 - 21个月），需要进一步治疗。在平均32个月的随访中，平均Snellen视力提高1±4行（范围，下降3行至提高7行）。
单独使用连续抗血管内皮生长因子治疗或联合光动力疗法巩固治疗脉络膜骨瘤所致脉络膜新生血管，可实现解剖学改善并使视力有适度提高。
